Endogenex vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endogenex develops the ReCET System, a catheter-based endoscopic device that remodels duodenal tissue to treat Type 2 diabetes without surgery; raised $25M Series B in 2024; completed European clinical trials with positive glycemic outcomes;
About
Endogenex is a medical device company headquartered in New Hope, Minnesota, developing endoscopic therapies for metabolic diseases. Its flagship product, the ReCET (Re-Cellularization via Electroporation Therapy) System, uses a catheter-based approach to deliver controlled electrical pulses to the duodenal lining. This non-surgical procedure remodels the duodenal epithelium — the tissue layer believed to play a key role in insulin resistance and glucose regulation — restoring more normal metabolic signaling without removing or bypassing anatomy.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.